hiPSC-GEP Transplantation for White Matter Stroke Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively enhance brain recovery or prevent the expansion of white matter stroke (WMS) lesions, as they do not adequately address the damage to astrocytes, axons, and myelin, leading to persistent cognitive and motor impairments.
Innovation Solution
Transplantation of human induced pluripotent stem cell-derived glial-enriched progenitors (hiPSC-GEPs) that differentiate into astrocytes, promoting endogenous oligodendrocyte proliferation and remyelination, which are administered into or adjacent to the infarct core in the brain to stimulate repair and recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for white matter stroke, then treatment is provided, but brain recovery is not enhanced and lesion expansion is not prevented
Solution Approach 1:
The patent uses induced pluripotent stem cell-derived glial-enriched progenitors as intermediary cells that migrate to the injured white matter and differentiate into astrocytes and oligodendrocytes. These intermediary cells facilitate repair by promoting remyelination and reducing inflammation, thereby enhancing brain recovery beyond what conventional therapies achieve alone.
2Reliability
If cell transplantation is performed to repair white matter damage, then neural repair may be achieved, but the specific cellular constituents (astrocytes, axons, oligodendrocytes, myelin) are not adequately addressed
Solution Approach 1:
The patent employs glial-enriched progenitors that are specifically differentiated to match the local cellular requirements of white matter tissue. These progenitors preferentially differentiate into astrocytes and oligodendrocytes, which are the specific cellular constituents damaged in white matter stroke, thereby providing locally adapted repair rather than generic neural tissue replacement.
3Strength
If myelin damage is not addressed, then axons become vulnerable to degeneration and lesion expansion occurs, but current therapies do not promote remyelination
Solution Approach 1:
The patent administers glial-enriched progenitors at the subacute stage (7 days post-stroke) before extensive axonal degeneration and lesion expansion occur. This preliminary action allows the transplanted cells to differentiate into oligodendrocytes and promote remyelination of vulnerable axons before they degenerate, and to suppress inflammatory responses that would drive lesion expansion.
Data Source
AI summary
In various embodiments methods and compositions for improving a recovery of a subject after a cerebral ischemic injury, such as white matter stroke are provided. In certain embodiments, the methods involve administering human induced pluripotent glial enriched progenitor cells into the brain of the subject.